GenMark Diagnostics (GNMK) 10-Q 30 Oct 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 28, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'GenMark Diagnostics, Inc.	'
Entity Central Index Key	'0001487371	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Amendment Flag	'false	'
Entity Common Stock, Shares Outstanding	'	41,734,301

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$25,658	$35,723
Marketable securities	53,590	69,866
Accounts receivable, net of allowances of $2,702 and $2,736, respectively	2,709	2,859
Inventories	1,532	2,102
Prepaid expenses and other current assets	1,229	552
Total current assets	84,718	111,102
Property and equipment, net	10,190	8,591
Intangible assets, net	1,934	1,197
Restricted cash	758	758
Other long-term assets	118	106
Total assets	97,718	121,754
Current liabilities	'	'
Accounts payable	3,307	3,863
Accrued compensation	5,132	3,375
Other current liabilities	3,113	2,999
Total current liabilities	11,552	10,237
Long-term liabilities	'	'
Deferred rent	1,488	1,601
Other non-current liabilities	114	748
Total liabilities	13,154	12,586
Stockholders’ equity	'	'
Preferred stock, $0.0001 par value; 5,000 authorized, none issued	0	0
Common stock, $0.0001 par value; 100,000 authorized; 41,726 and 41,520 shares issued and outstanding as of September 30, 2014 and December 31, 2013, respectively	4	4
Additional paid-in capital	338,415	333,363
Accumulated deficit	-253,859	-224,209
Accumulated other comprehensive income	4	10
Total stockholders’ equity	84,564	109,168
Total liabilities and stockholders’ equity	$97,718	$121,754

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]	'	'
Accounts receivable - net of allowance	$2,702	$2,736
Preferred stock, par value	$0.00	$0.00
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Common stock, par value	$0.00	$0.00
Common stock, authorized	100,000,000	100,000,000
Common stock, issued	41,749,000	41,520,000
Common stock, outstanding	41,749,000	41,520,000

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue	'	'	'	'
Product revenue	$6,233	$4,521	$20,593	$20,627
License and other revenue	67	116	175	325
Total revenue	6,300	4,637	20,768	20,952
Cost of revenue	2,692	4,138	9,591	12,373
Gross profit	3,608	499	11,177	8,579
Operating expenses	'	'	'	'
Sales and marketing	3,159	4,916	9,516	9,830
General and administrative	2,817	2,476	8,760	7,572
Research and development	7,904	5,398	23,297	15,786
Total operating expenses	13,880	12,790	41,573	33,188
Loss from operations	-10,272	-12,291	-30,396	-24,609
Other income (expense)	'	'	'	'
Interest income	228	203	783	413
Interest expense	-14	-3	-18	-17
Other income (expense)	-216	1,297	-611	1,232
Total other income (expense)	-2	1,497	154	1,628
Loss before provision for income taxes	-10,274	-10,794	-30,242	-22,981
Income tax expense (benefit)	-616	23	-591	30
Net loss	-9,658	-10,817	-29,651	-23,011
Net loss per share, basic and diluted	($0.23)	($0.30)	($0.72)	($0.69)
Weighted average number of shares outstanding, basic and diluted	41,446	35,987	41,273	33,331
Other comprehensive loss	'	'	'	'
Net loss	-9,658	-10,817	-29,651	-23,011
Net unrealized gains (losses) on marketable securities, net of tax	-3	21	6	12
Comprehensive loss	($9,661)	($10,796)	($29,645)	($22,999)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Cash Flows (Unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Operating activities	'	'
Net loss	($29,651)	($23,011)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	1,870	1,912
Amortization of premiums on marketable securities	577	133
Stock-based compensation	4,478	2,697
Provision for bad debt	0	2,720
Non-cash inventory adjustments	517	675
Changes in operating assets and liabilities:	'	'
Accounts receivable	151	-1,885
Inventories	209	-216
Prepaid expenses and other assets	-691	-263
Accounts payable	-318	570
Accrued compensation	1,757	29
Other liabilities	-1,131	-861
Net cash used in operating activities	-22,232	-17,500
Investing activities	'	'
Change in restricted cash	0	585
Payments for intellectual property licenses	-350	-888
Purchases of property and equipment	-3,699	-3,273
Purchases of available-for-sale securities	-28,054	-52,841
Proceeds from sales of marketable securities	7,497	4,250
Maturities of marketable securities	36,250	800
Net cash provided by (used in) investing activities	11,644	-51,367
Financing activities	'	'
Proceeds from issuance of common stock	373	86,247
Costs incurred in conjunction with public offering	0	-5,180
Principal repayment of borrowings	-51	-706
Proceeds from borrowings	0	166
Proceeds from stock option exercises	201	364
Net cash provided by financing activities	523	80,891
Net increase (decrease) in cash and cash equivalents	-10,065	12,024
Cash and cash equivalents at beginning of period	35,723	51,250
Cash and cash equivalents at end of period	25,658	63,274
Non-cash investing and financing activities	'	'
Transfer of instruments from property and equipment to inventory	156	431
Property and equipment costs included in accounts payable	364	308
Intellectual property acquisitions included in other current liabilities	550	556
Supplemental cash flow disclosures	'	'
Cash paid for income taxes, net	27	8
Cash received for interest	783	413
Cash paid for interest	$18	$17

Organization_and_Basis_of_Pres

Organization and Basis of Presentation	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization and Basis of Presentation	'
	Organization and Basis of Presentation
	GenMark Diagnostics, Inc., the Company or GenMark, was formed by Osmetech plc, or Osmetech, as a Delaware corporation in February 2010, and had no operations prior to its initial public offering, or the IPO, which was completed in June 2010. Immediately prior to the closing of the IPO, GenMark acquired all of the outstanding ordinary shares of Osmetech in a reorganization under the applicable laws of the United Kingdom. As a result of the reorganization, all of the issued ordinary shares in Osmetech were cancelled in consideration of: (i) the issuance of common stock of GenMark to the former shareholders of Osmetech; and (ii) the issuance of new shares in Osmetech to GenMark. Following the reorganization, Osmetech became a wholly-owned subsidiary controlled by GenMark, and the former shareholders of Osmetech received shares of GenMark. Any historical discussion of GenMark relates to Osmetech and its consolidated subsidiaries prior to the reorganization. In September 2012, GenMark placed Osmetech into liquidation to simplify its corporate structure. The liquidation of Osmetech was completed in the fourth quarter of 2013.
	The reorganization was deemed to be a transaction under common control; therefore, GenMark accounted for the reorganization in a manner similar to a pooling-of-interests, meaning:
	i.assets and liabilities were carried over at their respective carrying values;
	ii.common stock was carried over at the nominal value of the shares issued by GenMark;
	iii.additional paid-in capital represented the difference between the nominal value of the shares issued by GenMark, and the total of the additional paid-in capital and nominal value of Osmetech’s shares cancelled pursuant to the reorganization; and
	iv.the accumulated deficit represented the aggregate of the accumulated deficit of Osmetech and GenMark.
	Once the reorganization became effective, all stock options granted under the Osmetech plc 2003 U.S. Equity Compensation Plan, long term incentive awards and all warrants issued by Osmetech were exchanged for options and warrants exercisable for common stock of the Company.
	Basis of Presentation
	The accompanying financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses from operations since its inception and had an accumulated deficit of $253,859,000 as of September 30, 2014. Management expects operating losses to continue for the foreseeable future. The Company's ability to transition to profitable operations is dependent upon achieving a level of revenues adequate to support its cost structure through expanding its product offerings and consequently increasing its product revenues. Cash, cash equivalents and marketable securities as of September 30, 2014 were $79,248,000. The Company has prepared cash flow forecasts which indicate, based on the Company’s current cash resources available, that the Company will have sufficient resources to fund its business for at least the next 12 months.
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP, and applicable regulations of the U.S. Securities and Exchange Commission, or the SEC, and should be read in conjunction with the audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013 filed with the SEC on March 11, 2014. These unaudited condensed consolidated financial statements reflect all adjustments that are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. These adjustments are of a normal, recurring nature. Interim period operating results may not be indicative of the operating results for the full year or any future period.
	Segment Information
	The Company currently operates in one reportable business segment, which encompasses the development, manufacturing, sales and support of instruments and molecular tests based on its proprietary eSensor® detection technology. Substantially all of the Company’s operations and assets are in the United States of America.
	Recent Accounting Pronouncements
	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or the FASB, or other standard setting bodies that the Company adopts as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial condition or results of operations upon adoption.
	Cash, Cash Equivalents and Marketable Securities
	Cash and cash equivalents consist of cash on deposit with banks, money market instruments and certificates of deposit with original maturities of three months or less at the date of purchase. Marketable securities consist of certificates of deposit, corporate notes, commercial paper, U.S. government treasury securities and securities of government-sponsored entities that mature in greater than three months. Marketable securities are accounted for as "available-for-sale" with the carrying amounts reported in the balance sheets stated at cost, which approximates their fair market value, with unrealized gains and losses, if any, reported as a separate component of stockholders' equity and included in comprehensive loss.
	Receivables
	Accounts receivable consist of amounts due to the Company for sales to customers and are recorded net of an allowance for doubtful accounts. The allowance for doubtful accounts is determined based on an assessment of the collectability of specific customer accounts, the aging of accounts receivable, and a reserve for unknown items based upon the Company’s historical experience.
	Restricted Cash
	Restricted cash represents amounts designated for uses other than current operations and included $758,000 as of September 30, 2014, which is held as security for the Company’s letter of credit with Banc of California related to the Company's facility lease.
	Use of Estimates
	The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes thereto. The Company’s significant estimates included in the preparation of the financial statements are related to accounts receivable, inventories, property and equipment, intangible assets, employee related compensation accruals, warranty liabilities, tax valuation accounts and stock-based compensation. Actual results could differ from those estimates.
	Product Warranties
	The Company generally offers a one-year warranty for its systems sold to customers and typically up to a sixty day warranty for consumables. Factors that affect the Company’s warranty reserves include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary.
	Intangible Assets
	Intangible assets are comprised of licenses or sublicenses to technology covered by patents owned by third parties, and are amortized on a straight-line basis over the expected useful lives of these assets, which is generally 10 years. Amortization of licenses typically begins upon the Company obtaining access to the licensed technology and is recorded in cost of revenues for licenses supporting commercialized products. The amortization of licenses to technology supporting products in development is recorded in research and development expenses.
	Impairment of Long-Lived Assets
	The Company assesses the recoverability of long-lived assets, including intangible assets, by periodically evaluating the carrying value whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If impairment is indicated, the Company writes down the carrying value of the asset to its estimated fair value. This fair value is primarily determined based on estimated discounted cash flows.
	Inventories
	Inventories are stated at the lower of cost (first-in, first-out) or market and include direct labor, materials, and manufacturing overhead. The Company periodically reviews inventory for evidence of slow-moving or obsolete parts, and writes inventory down to market value, as needed. This write down is based on management’s review of inventories on hand, compared to estimated future usage and sales, shelf-life assumptions, and assumptions about the likelihood of obsolescence. If actual market conditions are less favorable than those projected by the Company, additional inventory write-downs may be required. Inventory impairment charges establish a new cost basis for inventory and charges are not reversed subsequently to income, even if circumstances later suggest that increased carrying amounts are recoverable.
	Property and Equipment, net
	Property, equipment and leasehold improvements are recorded at cost and depreciated using the straight-line method over the assets’ estimated useful lives, which are identified below. Repair and maintenance costs are expensed as incurred.
	Machinery and laboratory equipment	3 - 5 years
	Instruments	4 years
	Office equipment	5 years
	Leasehold improvements	over the shorter of the remaining life of the lease or the useful economic life of the asset
	Income Taxes
	Current income tax expense is the amount of income taxes expected to be payable for the current year. A deferred income tax liability or asset is established for the expected future tax consequences resulting from the differences in financial reporting and tax bases of assets and liabilities. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. A full valuation allowance has been recorded against the Company’s net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the future. The Company provides for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement standards prescribed by the authoritative guidance on income taxes. Amounts for uncertain tax positions are adjusted in periods when new information becomes available or when positions are effectively settled. The Company recognizes accrued interest related to uncertain tax positions as a component of income tax expense.
	A tax position that is more likely than not to be realized is measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement with the taxing authority that has full knowledge of all relevant information. Measurement of a tax position that meets the more likely than not threshold considers the amounts and probabilities of the outcomes that could be realized upon settlement using the facts, circumstances and information available at the reporting date.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2014
Compensation Related Costs [Abstract]	'
Stock-Based Compensation	'
	Stock-Based Compensation
	The Company recognizes stock-based compensation expense related to stock options, restricted stock awards and restricted stock units granted to employees and directors in exchange for services and employee stock purchases related to the Company's 2013 Employee Stock Purchase Plan, or the ESPP. Stock-based compensation expense is based on the fair value of the applicable award utilizing various assumptions regarding the underlying attributes of the award. Stock-based compensation expense is recorded in cost of sales, sales and marketing, research and development, and general and administration expenses based on the employee's respective function.
	The estimated fair value of stock options granted, net of forfeitures expected to occur during the vesting period, is amortized as compensation expense on a straight-line basis to reflect vesting as it occurs. The expense is derived from the Black-Scholes Option Pricing Model that uses several judgment-based variables to calculate the expense. The inputs include the expected term of the stock option, the expected volatility and other factors.
	•    Expected Term. Expected term represents the period that the stock-based awards are expected to be outstanding and is determined by using the simplified method.
	•    Expected Volatility. Expected volatility represents the volatility in the Company’s estimated stock price over the expected term of the stock option and is determined by review of the Company’s and similar companies’ historical experience.
	•    Expected Dividend. The Black-Scholes Option Pricing Model calls for a single expected dividend yield as an input. The Company assumed no dividends as it has never paid dividends and has no current plans to do so.
	•    Risk-Free Interest Rate. The risk-free interest rate used in the Black-Scholes Option Pricing Model is based on published U.S. Treasury rates in effect at the time of grant for periods corresponding with the expected term of the option.
	The compensation expense related to the grant of restricted stock awards or units is calculated as the fair market value of the stock on the grant date as further adjusted to reflect expected forfeitures.
	Employee participation in the Company's 2010 Equity Incentive Plan, or the 2010 Plan, is at the discretion of the Compensation Committee of the Board of Directors of the Company. All stock options granted under the 2010 Plan are exercisable at a per share price equal to the closing quoted market price of a share of the Company’s stock on the NASDAQ Global Market on the grant date and generally vest over a period of between one and four years.
	Stock options are generally exercisable for a period of up to 10 years after grant and are typically forfeited if employment is terminated before the options vest. As of September 30, 2014, there were 451,392 shares available for future grant under the 2010 Plan. Each grant of stock options, restricted stock awards and restricted stock units reduces the number of shares available for grant under the 2010 Plan.
	The following table summarizes stock option activity during the nine months ended September 30, 2014:
		Number of		Weighted Average Exercise Price		Weighted Average Contractual Life (Years)	Aggregate Intrinsic Value
		Shares
	Outstanding as of December 31, 2013	1,821,216		$	6.89	6.74	$	7,996,581
	Granted	938,416		11.91
	Exercised	-41,670		4.82
	Cancelled	-171,015		9.37
	Outstanding as of September 30, 2014	2,546,947		$	8.61	7.27	$	4,390,518
	Exercisable as of September 30, 2014	1,276,813		$	6.14	5.89	$	3,945,518
	The following table presents the weighted average assumptions used by the Company to estimate the fair value of stock options granted, as well as the resulting weighted average fair values for the nine months ended September 30, 2014:
		Nine Months Ended
		September 30,
		2014		2013
	Expected volatility	69	%	74	%
	Expected life (years)	6.08		6.08
	Risk free interest rate	1.82	%	1.14	%
	Expected dividend yield	—	%	—	%
	Weighted average fair value	$7.47		$7.28
	In March 2013, the Company transitioned to granting restricted stock units under the 2010 Plan in lieu of granting restricted stock awards. The Company’s restricted stock award and restricted stock unit activity for the nine months ended September 30, 2014 was as follows:
		Restricted Stock Awards				Restricted Stock Units
		Number of		Weighted		Number of	Weighted
		Shares		Average		Shares	Average
				Grant Date			Grant Date
				Fair Value			Fair Value
	Unvested as of December 31, 2013	508,606		$	4.54	474,847	$	11.51
	Granted	—		—		517,419	11.71
	Vested	-250,207		4.36		-162,134	12.02
	Cancelled or expired	-38,359		5.57		-84,531	11.69
	Unvested as of September 30, 2014	220,040		$	4.56	745,601	$	11.52
	As of September 30, 2014, there was $905,000 of unrecognized compensation cost related to unvested restricted stock awards, which is expected to be recognized over a weighted average period of 1.42 years. The total fair value of restricted stock awards that vested during the nine months ended September 30, 2014 and 2013 was $2,978,000 and $1,287,000, respectively. As of September 30, 2014, there was $7,061,000 of unrecognized compensation cost related to unvested restricted stock units, which is expected to be recognized over a weighted average period of 2.85 years. The total fair value of restricted stock units that vested during the nine months ended September 30, 2014 and 2013 was $1,791,000 and $39,000, respectively.
	Restricted stock awards or units may be granted at the discretion of the Compensation Committee of the Board of Directors under the 2010 Plan in connection with the hiring or retention of personnel and are subject to certain conditions. Restrictions expire at certain dates in accordance with specific provisions in the applicable award agreement. During the nine months ended September 30, 2014 and 2013, stock compensation expense for restricted stock units and awards was $2,453,000 and $1,338,000, respectively.
	The Company issued performance-based restricted stock units in March 2014. The vesting and issuance of Company stock pursuant to these awards depends on obtaining regulatory clearance of various products within a defined timeline. Stock-based compensation expense for performance-based awards is recognized when it is probable that the applicable performance criteria will be satisfied. The probability of achieving the relevant performance criteria is evaluated on a quarterly basis. During the nine months ended September 30, 2014, expense of $89,000 was recognized, based on the probability of achieving the applicable performance criteria under these awards. As of September 30, 2014, there was $44,000 of unrecognized stock-based compensation expense related to these awards.
	Employee Stock Purchase Plan
	Following the adoption of the ESPP by the Company’s Board of Directors in March 2013, the Company's stockholders approved the ESPP in May 2013 at the Company's Annual Meeting of Stockholders. A total of 650,000 shares of the Company’s common stock were originally reserved for issuance under the ESPP, which permits eligible employees to purchase common stock at a discount through payroll deductions.
	The price at which stock is purchased under the ESPP is equal to 85% of the fair market value of the Company's common stock on the first or the last day of the offering period, whichever is lower. Generally, each offering under the ESPP will be for a period of six months as determined by the Company's Board of Directors; provided that no offering period may exceed 27 months. Employees may invest up to 10% of their qualifying gross compensation through payroll deductions. In no event may an employee purchase more than 1,500 shares of common stock during any six-month offering period. As of September 30, 2014, there were 576,741 shares of common stock available for issuance under the ESPP. The ESPP is a compensatory plan as defined by the authoritative guidance for stock compensation, therefore, stock-based compensation expense has been recorded during the nine months ended September 30, 2014.

Net_Loss_per_Common_Share

Net Loss per Common Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Net Loss per Common Share	'
	Net Loss per Common Share
	Basic net loss per share is calculated by dividing loss available to stockholders of the Company's common stock (the numerator) by the weighted average number of shares of the Company's common stock outstanding during the period (the denominator). Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted loss per share is calculated in a similar way to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the dilutive potential shares had been issued, unless the effect would be anti-dilutive.
	The computations of diluted net loss per share for the three and nine month periods ended September 30, 2014 and 2013 did not include the effects of the following stock options and restricted stock awards which were outstanding as of the end of each period because the inclusion of these securities would have been anti-dilutive (in thousands):
		Three Months Ended September 30,		Nine Months Ended September 30,
		2014	2013	2014	2013
	Options outstanding to purchase common stock	2,547	1,830	2,547	1,830
	Unvested restricted stock	1,009	1,038	1,009	1,038
	Total	3,556	2,868	3,556	2,868

Inventories

Inventories	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories
	Inventory on hand as of September 30, 2014 and December 31, 2013 was comprised of the following (in thousands):
		September 30, 2014		December 31, 2013
	Raw materials	$	496	$	713
	Work-in-process	377		437
	Finished goods	659		952
		$	1,532	$	2,102

Property_and_Equipment_net

Property and Equipment, net	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment, Net [Abstract]	'
Property and Equipment, net	'
	Property and Equipment, net
	Property and equipment as of September 30, 2014 and December 31, 2013 was comprised of the following (in thousands):
		September 30, 2014			December 31, 2013
	Property and equipment — at cost:
	Machinery and laboratory equipment	$	5,550		$	3,260
	Instruments	7,099			7,013
	Office equipment	1,455			1,325
	Leasehold improvements	4,179			3,755
	Total property and equipment — at cost	18,283			15,353
	Less: accumulated depreciation	(8,093		)	(6,762		)
	Property and equipment, net	$	10,190		$	8,591
	Depreciation expense was $638,000 and $791,000 for the three months ended September 30, 2014 and 2013, respectively, and was $1,707,000 and $1,684,000 for the nine months ended September 30, 2014 and 2013, respectively.

Intangible_Assets_net

Intangible Assets, net	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets, net	'
	Intangible Assets, net
	Intangible assets as of September 30, 2014 and December 31, 2013 were comprised of the following (in thousands):
		September 30, 2014						December 31, 2013
		Gross carrying amount			Accumulated amortization	Net carrying amount		Gross carrying amount		Accumulated amortization	Net carrying amount
	Intellectual property licenses	$	2,750		-816	$	1,934	$	2,409	-1,212	$	1,197
	Intellectual property licenses have a weighted average remaining amortization period of 7.61 years as of September 30, 2014. Amortization expense for the licenses was $64,000 and $84,000 for the three months ended September 30, 2014 and 2013, respectively, and was $163,000 and $228,000 for the nine months ended September 30, 2014 and 2013, respectively. Estimated future amortization expense for these licenses is as follows (in thousands):
	Fiscal Years Ending		Future Amortization Expense
	Remaining in 2014		$	64
	2015		257
	2016		254
	2017		254
	2018		254
	Thereafter		851
	Total		$	1,934

Loan_Payable

Loan Payable	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Loan Payable	'
	Loan Payable
	In September 2012, the Company entered into a term loan with Banc of California, consisting of the following two loans.
	1) The Company increased the letter of credit provided to its landlord of its Carlsbad, California facility to $758,000 from the previous letter of credit of $500,000. The increase in the letter of credit was required by the Company’s landlord in connection with the Company’s lease of additional space at this facility. This letter of credit was secured with $758,000 of restricted cash as of September 30, 2014.
	2) The Company obtained a variable rate term loan from Banc of California in the amount of $836,000 with an initial interest rate of 3.75% that expired in July 2013. As of December 31, 2013, the Company had repaid all outstanding amounts under this loan.

Leases

Leases	9 Months Ended
	Sep. 30, 2014
Leases [Abstract]	'
Leases	'
	Leases
	The Company has operating and capital lease agreements for its office, manufacturing, warehousing and laboratory space and for office equipment. Rent and operating expenses charged under these arrangements was $268,000 and $292,000 for the three months ended September 30, 2014 and 2013, respectively, and $858,000 and $757,000 for the nine months ended September 30, 2014 and 2013, respectively. Pursuant to the Company's lease agreements, a portion of the monthly rent has been deferred. The balance of deferred rent as of September 30, 2014 and December 31, 2013 was $1,636,000 and $1,725,000, respectively.
	As of September 30, 2014, the future minimum lease payments required over the next five years under the Company's lease arrangements are as follows (in thousands):
	Fiscal Years Ending	Future Minimum Lease Payments
	Remaining in 2014	$	267
	2015	1,084
	2016	1,116
	2017	1,123
	2018	1,156
	Thereafter	3,044
	Total	$	7,790

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The carrying amounts of financial instruments, such as cash equivalents, restricted cash, accounts receivable, and accounts payable approximate the related fair values due to the short-term maturities of these instruments.
	The Company uses a fair value hierarchy with three levels of inputs, of which the first two are considered observable and
	the last unobservable, to measure fair value:
	•	Level 1 — Quoted prices in active markets for identical assets or liabilities.
	•	Level 2 — Inputs, other than Level 1, that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	•	Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The following table presents the financial instruments measured at fair value on a recurring basis on the financial statements of the Company and the valuation approach applied to each class of financial instruments as of September 30, 2014 and December 31, 2013 (in thousands):
		September 30, 2014
		Quoted Prices		Significant		Significant		Total
		in Active		Other		Unobservable
		Markets for		Observable		Inputs
		Identical		Inputs		(Level 3)
		Assets		(Level 2)
		(Level 1)
	Money market funds (cash equivalents)	$	19,805	$	—	$	—	$	19,805
	Corporate notes and bonds	—		24,265		—		24,265
	U.S. government and agency securities	—		26,826		—		26,826
	Commercial paper	—		2,499		—		2,499
	Total	$	19,805	$	53,590	$	—	$	73,395
		December 31, 2013
		Quoted Prices		Significant		Significant		Total
		in Active		Other		Unobservable
		Markets for		Observable		Inputs
		Identical		Inputs		(Level 3)
		Assets		(Level 2)
		(Level 1)
	Money market funds (cash equivalents)	$	10,020	$	—	$	—	$	10,020
	Corporate notes and bonds	—		22,954		—		22,954
	U.S. government and agency securities	—		43,115		—		43,115
	Commercial paper	—		3,797		—		3,797
	Total	$	10,020	$	69,866	$	—	$	79,886
	Level 2 marketable securities are priced using quoted market prices for similar instruments or nonbinding market prices that are corroborated by observable market data. The Company uses inputs such as actual trade data, benchmark yields, broker/dealer quotes, and other similar data, which are obtained from quoted market prices, independent pricing vendors, or other sources, to determine the ultimate fair value of these assets and liabilities. The Company uses such pricing data as the primary input to make its assessments and determinations as to the ultimate valuation of its investment portfolio and has not made, during the periods presented, any material adjustments to such inputs.

Marketable_Securities

Marketable Securities	9 Months Ended
	Sep. 30, 2014
Investments, Debt and Equity Securities [Abstract]	'
Marketable Securities	'
	Marketable Securities
	The following table summarizes the Company’s marketable securities as of September 30, 2014 and December 31, 2013 (in thousands):
	September 30, 2014		Amortized Cost			Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
	Corporate notes and bonds		$	24,280		$	6	$	(21	)	$	24,265
	U.S. government and agency securities		26,821			8		(3		)	26,826
	Commercial paper		2,499			—		—			2,499
	Total		$	53,600		$	14	$	(24	)	$	53,590
	December 31, 2013		Amortized Cost			Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
	Corporate notes and bonds		$	22,949		$	12	$	(7	)	$	22,954
	U.S. government and agency securities		43,124			3		(12		)	43,115
	Commercial paper		3,797			—		—			3,797
	Total		$	69,870		$	15	$	(19	)	$	69,866
	The following table summarizes the maturities of the Company’s marketable securities as of September 30, 2014 (in thousands):
		Amortized Cost			Estimated Fair Value
	Due in one year or less	$	37,801		$	37,806
	Due after one year through two years	15,799			15,784
	Total	$	53,600		$	53,590

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter.
	As of September 30, 2014, the Company recorded a full valuation allowance against all of its net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the future.  Due to the Company's losses, it only records a tax provision or benefit related to uncertain tax positions and related interest and minimum tax payments or refunds. The Company recorded an income tax benefit of $591,000 for the nine months ended September 30, 2014 and income tax expense of $30,000 for the nine months ended September 30, 2013.
	During the third quarter, the Company reduced the amount of unrecognized tax benefits associated with uncertain tax positions by $610,000, including interest and penalties of $228,000, as a result of the expiration of applicable statute of limitations.
	The Company is subject to taxation in the United States and in various state jurisdictions. In previous years, the Company was also subject to income taxes in the United Kingdom based upon its legacy operations. As of September 30, 2014, the Company’s tax years after 2008 are subject to examination by the U.K. tax authorities. Except for net operating losses generated in prior years carrying forward to the current year, as of September 30, 2014, the Company is no longer subject to U.S. federal, state, or local examinations for years before 2009.

Organization_and_Basis_of_Pres1

Organization and Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses from operations since its inception and had an accumulated deficit of $253,859,000 as of September 30, 2014. Management expects operating losses to continue for the foreseeable future. The Company's ability to transition to profitable operations is dependent upon achieving a level of revenues adequate to support its cost structure through expanding its product offerings and consequently increasing its product revenues. Cash, cash equivalents and marketable securities as of September 30, 2014 were $79,248,000. The Company has prepared cash flow forecasts which indicate, based on the Company’s current cash resources available, that the Company will have sufficient resources to fund its business for at least the next 12 months.
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP, and applicable regulations of the U.S. Securities and Exchange Commission, or the SEC, and should be read in conjunction with the audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013 filed with the SEC on March 11, 2014. These unaudited condensed consolidated financial statements reflect all adjustments that are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. These adjustments are of a normal, recurring nature. Interim period operating results may not be indicative of the operating results for the full year or any future period.
Segment Information	'
	Segment Information
	The Company currently operates in one reportable business segment, which encompasses the development, manufacturing, sales and support of instruments and molecular tests based on its proprietary eSensor® detection technology. Substantially all of the Company’s operations and assets are in the United States of America.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or the FASB, or other standard setting bodies that the Company adopts as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial condition or results of operations upon adoption.
Cash and Cash Equivalents	'
	Cash, Cash Equivalents and Marketable Securities
	Cash and cash equivalents consist of cash on deposit with banks, money market instruments and certificates of deposit with original maturities of three months or less at the date of purchase. Marketable securities consist of certificates of deposit, corporate notes, commercial paper, U.S. government treasury securities and securities of government-sponsored entities that mature in greater than three months. Marketable securities are accounted for as "available-for-sale" with the carrying amounts reported in the balance sheets stated at cost, which approximates their fair market value, with unrealized gains and losses, if any, reported as a separate component of stockholders' equity and included in comprehensive loss.
Receivables	'
	Receivables
	Accounts receivable consist of amounts due to the Company for sales to customers and are recorded net of an allowance for doubtful accounts. The allowance for doubtful accounts is determined based on an assessment of the collectability of specific customer accounts, the aging of accounts receivable, and a reserve for unknown items based upon the Company’s historical experience.
Restricted Cash	'
	Restricted Cash
	Restricted cash represents amounts designated for uses other than current operations and included $758,000 as of September 30, 2014, which is held as security for the Company’s letter of credit with Banc of California related to the Company's facility lease.
Use of Estimates	'
	Use of Estimates
	The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes thereto. The Company’s significant estimates included in the preparation of the financial statements are related to accounts receivable, inventories, property and equipment, intangible assets, employee related compensation accruals, warranty liabilities, tax valuation accounts and stock-based compensation. Actual results could differ from those estimates.
Product Warranties	'
	Product Warranties
	The Company generally offers a one-year warranty for its systems sold to customers and typically up to a sixty day warranty for consumables. Factors that affect the Company’s warranty reserves include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary.
Intangible Assets	'
	Intangible Assets
	Intangible assets are comprised of licenses or sublicenses to technology covered by patents owned by third parties, and are amortized on a straight-line basis over the expected useful lives of these assets, which is generally 10 years. Amortization of licenses typically begins upon the Company obtaining access to the licensed technology and is recorded in cost of revenues for licenses supporting commercialized products. The amortization of licenses to technology supporting products in development is recorded in research and development expenses.
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets
	The Company assesses the recoverability of long-lived assets, including intangible assets, by periodically evaluating the carrying value whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If impairment is indicated, the Company writes down the carrying value of the asset to its estimated fair value. This fair value is primarily determined based on estimated discounted cash flows.
Inventories	'
	Inventories
	Inventories are stated at the lower of cost (first-in, first-out) or market and include direct labor, materials, and manufacturing overhead. The Company periodically reviews inventory for evidence of slow-moving or obsolete parts, and writes inventory down to market value, as needed. This write down is based on management’s review of inventories on hand, compared to estimated future usage and sales, shelf-life assumptions, and assumptions about the likelihood of obsolescence. If actual market conditions are less favorable than those projected by the Company, additional inventory write-downs may be required. Inventory impairment charges establish a new cost basis for inventory and charges are not reversed subsequently to income, even if circumstances later suggest that increased carrying amounts are recoverable.
Property and Equipment, net	'
	Property and Equipment, net
	Property, equipment and leasehold improvements are recorded at cost and depreciated using the straight-line method over the assets’ estimated useful lives, which are identified below. Repair and maintenance costs are expensed as incurred.
	Machinery and laboratory equipment	3 - 5 years
	Instruments	4 years
	Office equipment	5 years
	Leasehold improvements	over the shorter of the remaining life of the lease or the useful economic life of the asset
Income Taxes	'
	Income Taxes
	Current income tax expense is the amount of income taxes expected to be payable for the current year. A deferred income tax liability or asset is established for the expected future tax consequences resulting from the differences in financial reporting and tax bases of assets and liabilities. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. A full valuation allowance has been recorded against the Company’s net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the future. The Company provides for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement standards prescribed by the authoritative guidance on income taxes. Amounts for uncertain tax positions are adjusted in periods when new information becomes available or when positions are effectively settled. The Company recognizes accrued interest related to uncertain tax positions as a component of income tax expense.
	A tax position that is more likely than not to be realized is measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement with the taxing authority that has full knowledge of all relevant information. Measurement of a tax position that meets the more likely than not threshold considers the amounts and probabilities of the outcomes that could be realized upon settlement using the facts, circumstances and information available at the reporting date.

Organization_and_Basis_of_Pres2

Organization and Basis of Presentation (Tables)	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Estimated useful lives of property and equipment	'
	Property, equipment and leasehold improvements are recorded at cost and depreciated using the straight-line method over the assets’ estimated useful lives, which are identified below. Repair and maintenance costs are expensed as incurred.
	Machinery and laboratory equipment	3 - 5 years
	Instruments	4 years
	Office equipment	5 years
	Leasehold improvements	over the shorter of the remaining life of the lease or the useful economic life of the asset

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2014
Compensation Related Costs [Abstract]	'
Schedule of stock option activity	'
	he following table summarizes stock option activity during the nine months ended September 30, 2014:
		Number of		Weighted Average Exercise Price		Weighted Average Contractual Life (Years)	Aggregate Intrinsic Value
		Shares
	Outstanding as of December 31, 2013	1,821,216		$	6.89	6.74	$	7,996,581
	Granted	938,416		11.91
	Exercised	-41,670		4.82
	Cancelled	-171,015		9.37
	Outstanding as of September 30, 2014	2,546,947		$	8.61	7.27	$	4,390,518
	Exercisable as of September 30, 2014	1,276,813		$	6.14	5.89	$	3,945,518
Fair value assumptions of stock options	'
		Nine Months Ended
		September 30,
		2014		2013
	Expected volatility	69	%	74	%
	Expected life (years)	6.08		6.08
	Risk free interest rate	1.82	%	1.14	%
	Expected dividend yield	—	%	—	%
	Weighted average fair value	$7.47		$7.28
Summary of restricted stock award and restricted stock units activity	'
	The Company’s restricted stock award and restricted stock unit activity for the nine months ended September 30, 2014 was as follows:
		Restricted Stock Awards				Restricted Stock Units
		Number of		Weighted		Number of	Weighted
		Shares		Average		Shares	Average
				Grant Date			Grant Date
				Fair Value			Fair Value
	Unvested as of December 31, 2013	508,606		$	4.54	474,847	$	11.51
	Granted	—		—		517,419	11.71
	Vested	-250,207		4.36		-162,134	12.02
	Cancelled or expired	-38,359		5.57		-84,531	11.69
	Unvested as of September 30, 2014	220,040		$	4.56	745,601	$	11.52

Net_Loss_per_Common_Share_Tabl

Net Loss per Common Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Computations of diluted net loss per share	'
	The computations of diluted net loss per share for the three and nine month periods ended September 30, 2014 and 2013 did not include the effects of the following stock options and restricted stock awards which were outstanding as of the end of each period because the inclusion of these securities would have been anti-dilutive (in thousands):
		Three Months Ended September 30,		Nine Months Ended September 30,
		2014	2013	2014	2013
	Options outstanding to purchase common stock	2,547	1,830	2,547	1,830
	Unvested restricted stock	1,009	1,038	1,009	1,038
	Total	3,556	2,868	3,556	2,868

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Summary of inventory on hand	'
	Inventory on hand as of September 30, 2014 and December 31, 2013 was comprised of the following (in thousands):
		September 30, 2014		December 31, 2013
	Raw materials	$	496	$	713
	Work-in-process	377		437
	Finished goods	659		952
		$	1,532	$	2,102

Property_and_Equipment_net_Tab

Property and Equipment, net (Tables)	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment, Net [Abstract]	'
Property and equipment, net	'
	Property and equipment as of September 30, 2014 and December 31, 2013 was comprised of the following (in thousands):
		September 30, 2014			December 31, 2013
	Property and equipment — at cost:
	Machinery and laboratory equipment	$	5,550		$	3,260
	Instruments	7,099			7,013
	Office equipment	1,455			1,325
	Leasehold improvements	4,179			3,755
	Total property and equipment — at cost	18,283			15,353
	Less: accumulated depreciation	(8,093		)	(6,762		)
	Property and equipment, net	$	10,190		$	8,591

Intangible_Assets_net_Tables

Intangible Assets, net (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Summary of intangible assets	'
	Intangible assets as of September 30, 2014 and December 31, 2013 were comprised of the following (in thousands):
		September 30, 2014						December 31, 2013
		Gross carrying amount			Accumulated amortization	Net carrying amount		Gross carrying amount		Accumulated amortization	Net carrying amount
	Intellectual property licenses	$	2,750		-816	$	1,934	$	2,409	-1,212	$	1,197
Summary of estimated future amortization expense	'
	Estimated future amortization expense for these licenses is as follows (in thousands):
	Fiscal Years Ending		Future Amortization Expense
	Remaining in 2014		$	64
	2015		257
	2016		254
	2017		254
	2018		254
	Thereafter		851
	Total		$	1,934

Leases_Tables

Leases (Tables)	9 Months Ended
	Sep. 30, 2014
Leases [Abstract]	'
Schedule of future minimum lease payments	'
	As of September 30, 2014, the future minimum lease payments required over the next five years under the Company's lease arrangements are as follows (in thousands):
	Fiscal Years Ending	Future Minimum Lease Payments
	Remaining in 2014	$	267
	2015	1,084
	2016	1,116
	2017	1,123
	2018	1,156
	Thereafter	3,044
	Total	$	7,790

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Assets measured at fair value on a recurring basis	'
	The following table presents the financial instruments measured at fair value on a recurring basis on the financial statements of the Company and the valuation approach applied to each class of financial instruments as of September 30, 2014 and December 31, 2013 (in thousands):
		September 30, 2014
		Quoted Prices		Significant		Significant		Total
		in Active		Other		Unobservable
		Markets for		Observable		Inputs
		Identical		Inputs		(Level 3)
		Assets		(Level 2)
		(Level 1)
	Money market funds (cash equivalents)	$	19,805	$	—	$	—	$	19,805
	Corporate notes and bonds	—		24,265		—		24,265
	U.S. government and agency securities	—		26,826		—		26,826
	Commercial paper	—		2,499		—		2,499
	Total	$	19,805	$	53,590	$	—	$	73,395
		December 31, 2013
		Quoted Prices		Significant		Significant		Total
		in Active		Other		Unobservable
		Markets for		Observable		Inputs
		Identical		Inputs		(Level 3)
		Assets		(Level 2)
		(Level 1)
	Money market funds (cash equivalents)	$	10,020	$	—	$	—	$	10,020
	Corporate notes and bonds	—		22,954		—		22,954
	U.S. government and agency securities	—		43,115		—		43,115
	Commercial paper	—		3,797		—		3,797
	Total	$	10,020	$	69,866	$	—	$	79,886

Marketable_Securities_Tables

Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2014
Investments, Debt and Equity Securities [Abstract]	'
Company's available-for-sale investments	'
	The following table summarizes the Company’s marketable securities as of September 30, 2014 and December 31, 2013 (in thousands):
	September 30, 2014		Amortized Cost			Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
	Corporate notes and bonds		$	24,280		$	6	$	(21	)	$	24,265
	U.S. government and agency securities		26,821			8		(3		)	26,826
	Commercial paper		2,499			—		—			2,499
	Total		$	53,600		$	14	$	(24	)	$	53,590
	December 31, 2013		Amortized Cost			Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
	Corporate notes and bonds		$	22,949		$	12	$	(7	)	$	22,954
	U.S. government and agency securities		43,124			3		(12		)	43,115
	Commercial paper		3,797			—		—			3,797
	Total		$	69,870		$	15	$	(19	)	$	69,866
Company's available-for-sale maturities investments	'
	The following table summarizes the maturities of the Company’s marketable securities as of September 30, 2014 (in thousands):
		Amortized Cost			Estimated Fair Value
	Due in one year or less	$	37,801		$	37,806
	Due after one year through two years	15,799			15,784
	Total	$	53,600		$	53,590

Organization_and_Basis_of_Pres3

Organization and Basis of Presentation (Details)	9 Months Ended
	Sep. 30, 2014
Machinery and laboratory equipment [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Expected useful lives of these assets	'3 years
Machinery and laboratory equipment [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Expected useful lives of these assets	'5 years
Instruments [Member]	'
Property, Plant and Equipment [Line Items]	'
Expected useful lives of these assets	'4 years
Office equipment [Member]	'
Property, Plant and Equipment [Line Items]	'
Expected useful lives of these assets	'5 years
Leasehold improvements [Member]	'
Property, Plant and Equipment [Line Items]	'
Leasehold improvements	'over the shorter of the remaining life of the lease or the useful economic life of the asset

Organization_and_Basis_of_Pres4

Organization and Basis of Presentation (Details Textual) (USD $)	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
	Segment
Property, Plant and Equipment [Line Items]	'	'
Accumulated deficit	($253,859,000)	($224,209,000)
Cash and cash equivalents	79,248,000	'
Sufficient capital to fund its operations	'at least the next 12 months	'
Number of operating segment	1	'
Restricted cash	$758,000	'
Maximum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Expected useful lives of these assets	'10 years	'
Systems [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Products warranty period	'1 year	'
Reagents [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Products warranty period	'60 days	'

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	9 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Schedule of stock option activity	'	'
Number of Share options Outstanding, Beginning Balance	1,821,216	'
Number of Share options, Granted	938,416	'
Number of Share options, Exercised	-41,670	'
Number of Share options, Cancelled	-171,015	'
Number of Share options Outstanding, Ending Balance	2,546,947	1,821,216
Number of Share options, Exercisable	1,276,813	'
Weighted average exercise price Outstanding, Beginning Balance	$6.89	'
Weighted average exercise price, Granted	$11.91	'
Weighted average exercise price, Exercised	$4.82	'
Weighted average exercise price, Cancelled	$9.37	'
Weighted average exercise price Outstanding, Ending Balance	$8.61	$6.89
Weighted average exercise price, Exercisable	$6.14	'
Weighted Average Remaining Contractual Life, Outstanding (in years)	'7 years 3 months 7 days	'6 years 8 months 27 days
Weighted Average Remaining Contractual Life, Exercisable (in years)	'5 years 10 months 20 days	'
Aggregate intrinsic value, Outstanding	$4,391	$7,997
Aggregate intrinsic value, Exercisable	$3,946	'

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 1) (Options [Member], USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Options [Member]	'	'
Fair value of stock options granted	'	'
Expected volatility (%)	69.00%	74.00%
Expected life (years)	'6 years 29 days	'6 years 29 days
Risk free rate (%)	1.82%	1.14%
Expected dividend yield (%)	0.00%	0.00%
Weighted average fair value (usd per share)	$7.47	$7.28

StockBased_Compensation_Detail2

Stock-Based Compensation (Details 2) (USD $)	9 Months Ended
	Sep. 30, 2014
Restricted Stock Awards [Member]	'
Summary of restricted stock award and restricted stock units activity	'
Non-vested, Number of shares, Beginning balance	508,606
Number of shares, Granted	0
Number of shares, Vested	-250,207
Number of shares, Cancelled or expired	-38,359
Non-vested, Number of shares, Ending balance	220,040
Non-vested, Weighted average Grant Date Fair Value, Beginning balance	$4.54
Weighted Average Grant Date Fair Value, Granted	$0
Weighted average Grant Date Fair Value, Vested	$4.36
Weighted average Grant Date Fair Value, Cancelled or expired	$5.57
Non-vested, Weighted average Grant Date Fair Value, Ending balance	$4.56
Restricted Stock Units [Member]	'
Summary of restricted stock award and restricted stock units activity	'
Non-vested, Number of shares, Beginning balance	474,847
Number of shares, Granted	517,419
Number of shares, Vested	-162,134
Number of shares, Cancelled or expired	-84,531
Non-vested, Number of shares, Ending balance	745,601
Non-vested, Weighted average Grant Date Fair Value, Beginning balance	$11.51
Weighted Average Grant Date Fair Value, Granted	$11.71
Weighted average Grant Date Fair Value, Vested	$12.02
Weighted average Grant Date Fair Value, Cancelled or expired	$11.69
Non-vested, Weighted average Grant Date Fair Value, Ending balance	$11.52

StockBased_Compensation_Detail3

Stock-Based Compensation (Details Textual) (USD $)

9 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

1 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Mar. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Options [Member]

Options [Member]

Restricted Stock Awards [Member]

Restricted Stock Awards [Member]

Restricted Stock Awards [Member]

Restricted Stock Units [Member]

Restricted Stock Units [Member]

Performance Shares [Member]

2010 Plan [Member]

2010 Plan [Member]

2010 Plan [Member]

2010 Plan [Member]

Options [Member]

Options [Member]

Options [Member]

Options [Member]

Minimum [Member]

Maximum [Member]

Options [Member]

2013 Employee Stock Purchase Plan [Member]

2013 Employee Stock Purchase Plan [Member]

2013 Employee Stock Purchase Plan [Member]

Share-based compensation (Textual) [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options vested

'

'

'

'

'

'

'

'

'

'

'

'1 year

'4 years

'

'

'

'

'

Expiration period

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

Future grant of awards under the Plan

'

'

'

'

'

'

'

'

'

'

451,392

'

'

'

'

'

'

'

Granted Stock option

938,416

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total fair value of restricted stock vested

'

'

'

'

'

$2,978,000

$1,287,000

$1,791,000

$39,000

'

'

'

'

'

'

'

'

'

Stock compensation expense

4,478,000

2,697,000

'

'

'

2,453,000

1,338,000

'

'

89,000

'

'

'

'

'

'

'

'

Unrecognized compensation cost

'

'

'

'

905,000

905,000

'

7,061,000

'

44,000

'

'

'

'

'

'

'

'

Weighted average-period, cost is expected to be recognized

'

'

'

'

'1 year 5 months 1 day

'

'

'2 years 10 months 5 days

'

'

'

'

'

'

'

'

'

'

Number of shares, Granted

'

'

'

'

'

0

'

517,419

'

'

'

'

'

'

'

'

'

'

Weighted average fair value of options granted

'

'

'

'

'

$0

'

$11.71

'

'

'

'

'

'

'

'

'

'

Employee Stock Purchase Plan [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock reserved for future issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

576,741

650,000

Purchase price as a percent of the fair market value of the common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

85.00%

'

'

Maximum offering period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'27 months

'6 months

'

'

Maximum employee investment in ESPP as a percentage of gross compensation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

Maximum shares of common stock that can be puchased by each employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,500

'

'

Share-based compensation (Additional Textual) [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Remaining weighted average contractual term

'5 years 10 months 20 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value of options exercisable

$3,946,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected dividend yield

'

'

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average exercise price of stock option

$11.91

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net_Loss_per_Common_Share_Deta

Net Loss per Common Share (Details)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Computations of diluted net loss per share	'	'	'	'
Antidilutive securities excluded from calculation	3,556	2,868	3,556	2,868
Options [Member]	'	'	'	'
Computations of diluted net loss per share	'	'	'	'
Antidilutive securities excluded from calculation	2,547	1,830	2,547	1,830
Unvested restricted stock [Member]	'	'	'	'
Computations of diluted net loss per share	'	'	'	'
Antidilutive securities excluded from calculation	1,009	1,038	1,009	1,038

Inventories_Details

Inventories (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Summary of inventory on hand	'	'
Raw materials	$496	$713
Work-in-process	377	437
Finished goods	659	952
Total	$1,532	$2,102

Property_and_Equipment_net_Det

Property and Equipment, net (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Property and equipment-at cost:	'	'	'	'	'
Total property and equipment-at cost	$18,283	'	$18,283	'	$15,353
Less accumulated depreciation	-8,093	'	-8,093	'	-6,762
Property and equipment, net	10,190	'	10,190	'	8,591
Depreciation expense	638	791	1,707	1,684	'
Plant and machinery [Member]	'	'	'	'	'
Property and equipment-at cost:	'	'	'	'	'
Total property and equipment-at cost	5,550	'	5,550	'	3,260
Instruments [Member]	'	'	'	'	'
Property and equipment-at cost:	'	'	'	'	'
Total property and equipment-at cost	7,099	'	7,099	'	7,013
Office equipment [Member]	'	'	'	'	'
Property and equipment-at cost:	'	'	'	'	'
Total property and equipment-at cost	1,455	'	1,455	'	1,325
Leasehold improvements [Member]	'	'	'	'	'
Property and equipment-at cost:	'	'	'	'	'
Total property and equipment-at cost	$4,179	'	$4,179	'	$3,755

Intangible_Assets_net_Details

Intangible Assets, net (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Summary of intangible assets	'	'
Net carrying amount	$1,934	'
Licensed intellectual property [Member]	'	'
Summary of intangible assets	'	'
Gross carrying amount	2,750	2,409
Accumulated amortization	-816	-1,212
Net carrying amount	$1,934	$1,197

Intangible_Assets_net_Details_

Intangible Assets, net (Details 1) (USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Summary of estimated future amortization expense	'
Remaining in 2014	$64
2015	257
2016	254
2017	254
2018	254
Thereafter	851
Net carrying amount	$1,934

Intangible_Assets_net_Details_1

Intangible Assets, net (Details Textual) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Indefinite-lived Intangible Assets [Line Items]	'	'	'	'
Amortization expense for intangible assets	$64	$84	$163	$228
Licensed intellectual property [Member]	'	'	'	'
Indefinite-lived Intangible Assets [Line Items]	'	'	'	'
Weighted average amortization period	'	'	'7 years 7 months 10 days	'

Loan_Payable_Details_Textual

Loan Payable (Details Textual) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012	Jul. 31, 2013	Sep. 30, 2014
		New Letter of Credit [Member]	Previous Letter of Credit [Member]	Variable Rate Term Loan [Member]	Banc of California [Member]
		Letter of Credit [Member]	Letter of Credit [Member]	Term Loan [Member]	New Letter of Credit [Member]
					Letter of Credit [Member]
Loan Payable (Textual) [Abstract]	'	'	'	'	'
Increased amount of line of credit availability	'	$758,000	'	'	'
Restricted cash	758,000	'	'	'	758,000
Line of credit facility amount previously outstanding	'	'	500,000	'	'
Face amount of term loan	'	'	'	$836,000	'
Initial interest rate	'	'	'	3.75%	'

Leases_Details

Leases (Details) (USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Schedule of future minimum lease payments	'
Remaining in 2014	$267
2015	1,084
2016	1,116
2017	1,123
2018	1,156
Thereafter	3,044
Total future minimum payments	$7,790

Leases_Details_Textual

Leases (Details Textual) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Leases [Abstract]	'	'	'	'	'
Rent and operating expenses	$268	$292	$858	$757	'
Operating lease, deferred expense	$1,636	'	$1,636	'	$1,725

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Assets:	'	'
Assets, fair value	$73,395	$79,886
Quotes Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Assets:	'	'
Assets, fair value	19,805	10,020
Significant Other Observable Inputs (Level 2) [Member]	'	'
Assets:	'	'
Assets, fair value	53,590	69,866
Significant Unobservable Inputs (Level 3) [Member]	'	'
Assets:	'	'
Assets, fair value	0	0
Money market funds (cash equivalents) [Member]	'	'
Assets:	'	'
Assets, fair value	19,805	10,020
Money market funds (cash equivalents) [Member] | Quotes Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Assets:	'	'
Assets, fair value	19,805	10,020
Money market funds (cash equivalents) [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'
Assets:	'	'
Assets, fair value	0	0
Money market funds (cash equivalents) [Member] | Significant Unobservable Inputs (Level 3) [Member]	'	'
Assets:	'	'
Assets, fair value	0	0
Corporate notes and bonds [Member]	'	'
Assets:	'	'
Assets, fair value	24,265	22,954
Corporate notes and bonds [Member] | Quotes Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Assets:	'	'
Assets, fair value	0	0
Corporate notes and bonds [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'
Assets:	'	'
Assets, fair value	24,265	22,954
Corporate notes and bonds [Member] | Significant Unobservable Inputs (Level 3) [Member]	'	'
Assets:	'	'
Assets, fair value	0	0
U.S. government and agency securities [Member]	'	'
Assets:	'	'
Assets, fair value	26,826	43,115
U.S. government and agency securities [Member] | Quotes Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Assets:	'	'
Assets, fair value	0	0
U.S. government and agency securities [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'
Assets:	'	'
Assets, fair value	26,826	43,115
U.S. government and agency securities [Member] | Significant Unobservable Inputs (Level 3) [Member]	'	'
Assets:	'	'
Assets, fair value	0	0
Commercial paper [Member]	'	'
Assets:	'	'
Assets, fair value	2,499	3,797
Commercial paper [Member] | Quotes Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Assets:	'	'
Assets, fair value	0	0
Commercial paper [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'
Assets:	'	'
Assets, fair value	2,499	3,797
Commercial paper [Member] | Significant Unobservable Inputs (Level 3) [Member]	'	'
Assets:	'	'
Assets, fair value	$0	$0

Marketable_Securities_Details

Marketable Securities Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Company's available-for-sales investments	'	'
Amortized Cost	$53,600	$69,870
Gross Unrealized Gains	14	15
Gross Unrealized Losses	-24	-19
Fair Value	53,590	69,866
Corporate notes and bonds [Member]	'	'
Company's available-for-sales investments	'	'
Amortized Cost	24,280	22,949
Gross Unrealized Gains	6	12
Gross Unrealized Losses	-21	-7
Fair Value	24,265	22,954
U.S. government and agency securities [Member]	'	'
Company's available-for-sales investments	'	'
Amortized Cost	26,821	43,124
Gross Unrealized Gains	8	3
Gross Unrealized Losses	-3	-12
Fair Value	26,826	43,115
Commercial paper [Member]	'	'
Company's available-for-sales investments	'	'
Amortized Cost	2,499	3,797
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	$2,499	$3,797

Investments_Details_1

Investments (Details 1) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Company's available-for-sales investments	'	'
Less than 1 year, Amortized cost	$37,801	'
Due in 1 to 2 years, Amortized cost	15,799	'
Amortized Cost	53,600	69,870
Less than 1 year, Fair value	37,806	'
Due in 1 to 2 years, Fair value	15,784	'
Fair Value	$53,590	$69,866

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'	'	'	'	'
Income tax expense (benefit)	$616,000	($23,000)	$591,000	($30,000)	'
Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations	-610,000	'	'	'	'
Total amount of unrecognized tax benefits	382,000	'	382,000	'	382,000
Total balance of accrued interest and penalties related to uncertain tax positions	$228,000	'	$228,000	'	'